Percona Announces Line-up Of Speakers for Percona Live 2023, the World’s Largest Independent Database Conference
20.4.2023 16:00:00 EEST | Business Wire | Press release
Percona, a leader in enterprise-grade open source database software and services, will host the latest in its annual Percona Live conference series in Denver at the Marriott Tech Center from May 22-24, 2023. Percona Live is the longest-running independent open source database conference, covering a range of database and data management topics including cloud-native deployments, performance improvements, and real-world experience from some of the world’s largest database deployments.
The event will provide three days of hands-on tutorials, breakout sessions, keynote addresses, networking, and socializing with some of the world’s most experienced database professionals. Inspired by the Denver location, this year's event is themed CLIMB. The concept is about reaching peak database performance with open source databases and how Percona serves as a guide to doing so. At the event, industry experts will provide insights around some of the world's most popular databases — MySQL, PostgreSQL, and MongoDB — as well as other open source technologies such as Clickhouse, Vitess, and Kubernetes.
“Open source is essential to driving innovation, which is why we’re excited to bring back Percona Live in person following the success of last year's event in Austin,” commented Ann Schlemmer, CEO of Percona. “Over three days we will bring together the open source community to explore the latest technical advances around databases, approaches to data management and how we can deploy these tools more effectively. The conference enables the community to share their knowledge and experiences with one another to contribute to the future of open source.”
Keynote speakers at this year’s event include:
- Ann Schlemmer, CEO of Percona on The Future of Percona
-
Rachel Stephens, Senior Industry Analyst at RedMonk, As You Wish
Open source databases: a classic tale of true love and high adventure - Peter Zaitsev, Founder of Percona, Unlocking Data Freedom: Harnessing Open Source to Overcome Data Gravity
Additional topics include:
- Database Observability: Through the lens of SRE - Archana Jattigari, Credit Karma
- Why Machine Learning for Automatically Optimizing Databases Doesn't Work - Andy Pavlo, Carnegie Mellon University / OtterTune
- Operating a 120 TB MongoDB dataset on Kubernetes - David Noriega and Eric Fox, Adobe
- No Passwords, Please, We're Pinterest: Secure Identity-Based Authentication for MySQL - Ernie Souhrada, Pinterest
- Reducing Cost and Improving Performance with Data Modeling in Postgres - Charly Batista, Percona
- Upgrading to MySQL 8.0 - Michael Coburn, Percona
- What is the place of AI in SQL querying? - Tatiana Krupenya, DBeaver Corporation
- Pen-testing open source databases (MySQL and PostgreSQL) - Alexander Rubin, AWS
This year’s Percona Live is sponsored by Microsoft, AWS, Oracle, PlanetScale, FerretDB, Datavail, OtterTune, benchAnt, Victoria Metrics, Civo, and DBeaver just to name a few. For more information or to register for the conference, visit: https://www.percona.com/live/conferences
About Percona
Percona is widely recognized as a world-class open source database software, support, and services company. The organization is dedicated to helping businesses make databases and applications run better through a unique combination of expertise and open source software. Percona works with numerous global brands across many industries creating a unified experience to monitor, manage, secure, and optimize database environments on any infrastructure.
Percona equips organizations with the freedom to choose, the freedom to create, and the freedom to make a difference - helping them scale and innovate with speed as they grow. For more information, visit www.percona.com.
Databases run better with Percona.
Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005301/en/
Contact information
Press Contacts
Annabel Lander
Onebite for Percona
percona@onebite.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those
The Biggest Predictor of Business Growth Is Behavior30.4.2026 10:00:00 EEST | Press release
IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media & Technology, Healthcare, and Consumer Goods sectors. The report is the first of its kind to draw a direct line between how companies operate internally and their financial performance. Companies were surve
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 01:22:00 EEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 23:30:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new phase, shaped by the convergence of procedures, longevity and b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom